Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.59 |
| ▸ | KIF11 | P52732 | 7/20 | 0.55 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.41 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575608 | 1.00 | NR4A1 (0.59) | NR4A1NR4A2NR4A3KIF11KCNQ3 | |
| SCHEMBL4023529 | 1.00 | NR4A1 (0.59) | NR4A1NR4A2NR4A3KIF11KCNQ3 | |
| SCHEMBL2576659 | 0.82 | NR4A1 (0.54) | NR4A1NR4A2NR4A3KCNQ3KCNQ2 | |
| SCHEMBL2576657 | 0.82 | NR4A1 (0.54) | NR4A1NR4A2NR4A3KCNQ3KCNQ2 | |
| SCHEMBL313169 | 0.80 | KIF11 (0.75) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL2572494 | 0.79 | HDAC1 (0.53) | NR4A1NR4A2NR4A3KCNQ3KCNQ2 | |
| SCHEMBL20161985 | 0.79 | KIF11 (0.51) | NR4A1NR4A2NR4A3KIF11KCNQ3 | |
| SCHEMBL3203900 | 0.79 | HDAC1 (0.53) | NR4A1NR4A2NR4A3KCNQ3KCNQ2 | |
| SCHEMBL850429 | 0.78 | KIF11 (0.57) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL29620952 | 0.78 | KIF11 (0.57) | KIF11KCNQ3KCNQ2KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8247413-B2 | e.g. N-[2-(3-fluorophenyl)ethyl]-N'-isoquinolin-5-ylurea; opioid receptor inhibitor; analgesic, antiinflammatory agent; inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity | ABBOTT LABORATORIES (US) | 2012-08-21 | — | — | US | disclosed |
| EP-1478363-B1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LAB (US) | 2009-01-14 | — | — | EP | disclosed |
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2008-09-04 | — | — | US | disclosed |
| US-7335678-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBOTT LABORATORIES (US) | 2008-02-26 | — | — | US | disclosed |
| US-6933311-B2 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES (US) | 2005-08-23 | — | — | US | disclosed |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBOTT LABORATORIES | 2005-05-26 | — | — | US | disclosed |
| EP-1478363-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | Abbott Laboratories (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | ABBVIE INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2003070247-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | ABBOTT LABORATORIES (US) | 2003-08-28 | — | — | WO | disclosed |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | ABBVIE INC. | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214524-A1 | FUSED AZABICYCLIC COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR | TRPV1, TMEM109, VIPR1 | NR4A1 160/4885NR4A2 179/4885NR4A3 272/4885 |
| US-20030158198-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | NR4A1 146/4885NR4A2 183/4885NR4A3 273/4885 |
| US-20040157849-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, VIPR1, TMEM109 | NR4A1 155/4885NR4A2 194/4885NR4A3 290/4885 |
| US-20040209884-A1 | Fused azabicycic compounds that inhibit vanilloid receptor subtype 1(VR1) receptor | TRPV1, TMEM109, GPR55 | NR4A1 138/4885NR4A2 187/4885NR4A3 238/4885 |
| US-20050113576-A1 | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor | TRPV1, TMEM109, VIPR1 | NR4A1 160/4885NR4A2 179/4885NR4A3 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.